A multi-cancer global strategic oncology collaboration between Tokyo, Japan-headquartered Eisai Co. Ltd. and Merck & Co. Inc., the second such deal entered by Merck in the past seven months, was greeted with a near 10% rise in Eisai's share price on the Tokyo Stock Exchange on March 8, as investors digested the announcement, and another from the previous day, when Eisai reported positive top-line Phase III results for its potential sleep disorder therapy, lemborexant (see accompanying article).
Eisai And Merck & Co Supercharge Lenvima's Potential
A global collaboration potentially valued at nearly $6bn will see Eisai's oral tyrosine kinase inhibitor lenvatinib being evaluated in combination with Keytruda in multiple cancer types and indications.
More from Deals
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.